MedPath

Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men

Not Applicable
Completed
Conditions
Hiv Infection
Interventions
Procedure: Standard proctologic examination
Procedure: High resolution anoscopy
Procedure: Biopsy(ies) during High Resolution Anoscopy
Procedure: High Resolution Anoscopy biannually
Registration Number
NCT02287961
Lead Sponsor
ANRS, Emerging Infectious Diseases
Brief Summary

Multicentric epidemiological non-comparative study in France characterising evolution of anal Human papillomavirus (HPV) infection and related lesions and evaluating markers associated with the observed evolution.

Estimated enrolment: 500

Principal Outcomes

* Detection of high-grade cytological and histological anal lesions by high resolution anoscopy

* Spontaneous regression of high-grade anal lesions

* Detection of anal HPV infection

Intervention (procedure):

* Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

* Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

* High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):

- anal biopsy(ies) during HRA

Only if high-grade lesion:

- HRA biannually

Detailed Description

Intervention (procedure):

* Patient medical interview (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

* Standard proctologic examination with digital rectal examination and 2 anal swabs (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

* High resolution anoscopy (initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits)

Only if lesion suggestive of Anal Intraepithelial Neoplasia (AIN) detected during High Resolution Anoscopy (HRA):

- anal biopsy(ies) during HRA

Only if high-grade lesion (Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H), High grade Superficial Intra-epithelial Lesion (HSIL) or AIN2/3):

- HRA biannually

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
516
Inclusion Criteria
  • Men who have sex with men
  • At least 35 years old
  • HIV-positive (documented search of HIV infection, with HIV status determined according to HAS algorithm)
  • Signed informed consent
  • Affiliated to or beneficiary of French social security
  • All severity criteria and evolution of HIV disease are accepted (including AIDS stage and co-infections)
Exclusion Criteria
  • Contraindication to biopsy
  • History of anal cancer or pelvic radiotherapy
  • AIN2/3 treated during previous year
  • Current anticancer chemotherapy or within 24 months before inclusion
  • Difficulty in evaluation (anus reshaped and/or scarred)
  • Individual placed under judicial protection
  • Foreseen absence which may hamper participation; insufficient motivation; associated pathology with priority for care

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SubjectsHigh resolution anoscopy* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
SubjectsBiopsy(ies) during High Resolution Anoscopy* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
SubjectsHigh Resolution Anoscopy biannually* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
SubjectsStandard proctologic examination* Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits * Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy * High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
Primary Outcome Measures
NameTimeMethod
Evaluation of high-grade anal lesions by high resolution anoscopyInitial inclusion visit
Quantification of spontaneous regression of high-grade anal lesionsMonth 24
Evaluation of anal HPV infection by DNA, RNA and protein detectionInitial inclusion visit
Secondary Outcome Measures
NameTimeMethod
Evaluation of anal HPV infection by DNA, RNA and protein detectionMonth 24

Trial Locations

Locations (1)

Diaconesses

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath